Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Effects of simvastatin on circulating autoantibodies to oxidized LDL antigens: relation with immune stimulation markers
Statins exert a number of anti-inflammatory and immunomodulatory effects in vitro . However , the immunomodulatory effects in vivo are less clarified . In the present study , we investigated whether simvastatin treatment changed the levels of autoantibodies against specific oxidized LDL ( oxLDL ) antigens as well as their association with leukocyte activation markers . Eighty volunteers with mild-to-moderate hypercholesterolemia were r and omized to either simvastatin 40 mg or placebo for 6 weeks . Autoantibodies against apo B peptide antigens , C-reactive protein ( CRP ) and interleukin (IL)-6 in plasma were determined by ELISA . Subsets of circulating B and T cells were studied by flow cytometry . Simvastatin significantly reduced CRP by 26 % , whereas IL-6 remained unchanged . Levels of IgG against the apo B peptide P-240 ( amino acids 3586–3605 ) increased by 16 % ( p = 0.03 ) in the simvastatin group whereas autoantibody levels to other apo B peptides did not change . At baseline and after 6 weeks , the P-240 IgG levels were significantly correlated with the number of CD57+CD28 − CD8+T cells but not to other lymphocyte subsets or inflammatory markers . The P-240 IgG levels after 6 weeks simvastatin therapy was strongly correlated to the relative increase in CD57+CD28 − CD8+T cells ( p = 0.003 ) . Simvastatin treatment induced an increase in autoantibodies against an oxLDL antigen . The effect was related to an expansion of a CD8+T cell subset and may involve an immunostimulation by simvastatin
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .